Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02302209 · ClinicalTrials.gov registry record · Phase 1
Dyad Oxytocin Study (DOS)
A Phase 1 study, sponsored by University of California, San Francisco.
- Completed
- Registry status
- Phase 1
- Development phase
- 104
- Enrollment target
NCT02302209 is a Phase 1 study that has completed, run by University of California, San Francisco. The registered enrollment target is 104 participants.
The verdict
NCT02302209, a Phase 1 study, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 104 participants
- Enrollment target
Study Summary
The purpose of the investigators proposed study is twofold: 1) To investigate the role of the affiliative neuropeptide oxytocin in unhealthy interactions in families of patients with schizophrenia and families of patients with autism spectrum disorder, and 2) to investigate whether manipulation of this oxytocinergic system positively influences these family interactions.
Interventions
- DRUG Oxytocin
- OTHER Placebo Comparator
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 104 participants |
| Start Date | 2011-04 |
| Est. Completion | 2017-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02302209
The ClinicalTrials.gov registry entry for NCT02302209 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 104 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Oxytocin is the first listed.
NCT02302209 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02302209 about?
NCT02302209 is a clinical study titled "Dyad Oxytocin Study (DOS)". The purpose of the investigators proposed study is twofold: 1) To investigate the role of the affiliative neuropeptide oxytocin in unhealthy interactions in families of patients with schizophrenia and families of patients with autism spectrum disorder, and 2) to investigate whether manipulation of t...
What is the current status of trial NCT02302209?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 104 participants. The study started on 2011-04. Estimated completion is 2017-10.
What interventions are being tested in trial NCT02302209?
The interventions under investigation include: Oxytocin (DRUG), Placebo Comparator (OTHER).
Who is sponsoring clinical trial NCT02302209?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.